Trial Profile

An Open-label, Phase II Study of KN046 Evaluating the Efficacy and Safety of KN046 Plus Platinum-based Doublet Chemotherapy as First Line Therapy in Advanced Non-small Cell Lung Cancer Subjects.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erfonrilimab (Primary) ; Carboplatin; Paclitaxel; Pemetrexed
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use
Sponsors Alphamab Oncology; Jiangsu Alphamab Biopharmaceuticals

Most Recent Events

13 Sep 2022 Status changed from recruiting to completed, according to Results presented at the 47th European Society for Medical Oncology Congress.
13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
08 Jun 2021 Results (n=87; data cut off date- Jan 19, 2021) presented at the 57th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com